Zambon launches Xadago first in Germany, next in Switzerland

Zambon has launched Xadago (safinamide), an add-on therapy for treating idiopathic Parkinson's disease in its first market, Germany. It is the first new chemical entity to be approved for Parkinson's in 10 years.